(2R)-4-[4-(4-chloro-2-fluorophenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-methyl-2-2-(methylsulfonyl)butanamide | 1312473-62-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (2R)-4-[4-(4-chloro-2-fluorophenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-methyl-2-2-(methylsulfonyl)butanamide
• 英文别名: (2R)-4-[4-(4-chloro-2-fluorophenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-methyl-2-(methylsulfonyl)butanamide；(2R)-4-[4-(4-chloro-2-fluorophenyl)-2-oxopyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide
• CAS: 1312473-62-3
• 化学式: C₁₇H₁₈ClFN₂O₅S
• 分子量: 416.858
• InChiKey: ODGRPKMHEBNTQP-QGZVFWFLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  4-碘-2-吡啶酮 在 Pd EnCat 盐酸 、 水 、 potassium carbonate 、 1-羟基苯并三唑 、 caesium carbonate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 potassium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 16.0h， 生成 (2R)-4-[4-(4-chloro-2-fluorophenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-methyl-2-2-(methylsulfonyl)butanamide
  参考文献：
  名称：

  [EN] N-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS
  [FR] DÉRIVÉS D'ACIDE HYDROXAMIQUE À LIAISON N, UTILES COMME AGENTS ANTIBACTÉRIENS

  摘要：

  本发明涉及一类新的羟肟酸衍生物，它们作为LpxC抑制剂的用途，更具体地用于治疗细菌感染。公式（I）。

  公开号：

  WO2011073845A1

文献信息

• N-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents
  申请人：Brown Matthew Frank

  公开号：US20120258948A1

  公开（公告）日：2012-10-11

  The present invention is directed to a new class of hydroxamic acid derivatives of formula I, wherein the variables G, T, D, L, R 1 , R 2 , R 3 are as described herein, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections in a patient in need thereof.

  本发明涉及一种新的羟肟酸衍生物类别，其化学式为I，其中变量G，T，D，L，R1，R2，R3如本文所述，其用作LpxC抑制剂，更具体地用于治疗有需要的患者的细菌感染。
• N-linked hydroxamic acid derivatives useful as antibacterial agents
  申请人：Brown Matthew Frank

  公开号：US08664401B2

  公开（公告）日：2014-03-04

  The present invention is directed to a new class of hydroxamic acid derivatives of formula I, wherein the variables G, T, D, L, R1, R2, R3 are as described herein, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections in a patient in need thereof.

  本发明涉及一种新的羟肟酸衍生物类别，其化学式为I，其中变量G、T、D、L、R1、R2、R3如本文所述，它们的用途是LpxC抑制剂，更具体地用于治疗患有细菌感染的患者。
• N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents
  申请人：Pfizer Inc.

  公开号：US20140128363A1

  公开（公告）日：2014-05-08

  The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.

  本发明涉及一种新的羟肟酸衍生物类，其用作LpxC抑制剂，更具体地用于治疗细菌感染。
• N-link hydroxamic acid derivatives useful as antibacterial agents
  申请人：Pfizer Inc.

  公开号：US09018384B2

  公开（公告）日：2015-04-28

  The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.

  本发明涉及一种新型羟肟酸衍生物，其作为LpxC抑制剂的用途，更具体地用于治疗细菌感染。
• Pyridone Methylsulfone Hydroxamate LpxC Inhibitors for the Treatment of Serious Gram-Negative Infections
  作者：Justin I. Montgomery、Matthew F. Brown、Usa Reilly、Loren M. Price、Joseph A. Abramite、Joel Arcari、Rose Barham、Ye Che、Jinshan Michael Chen、Seung Won Chung、Elizabeth M. Collantes、Charlene Desbonnet、Matthew Doroski、Jonathan Doty、Juntyma J. Engtrakul、Thomas M. Harris、Michael Huband、John D. Knafels、Karen L. Leach、Shenping Liu、Anthony Marfat、Laura McAllister、Eric McElroy、Carol A. Menard、Mark Mitton-Fry、Lisa Mullins、Mark C. Noe、John O’Donnell、Robert Oliver、Joseph Penzien、Mark Plummer、Veerabahu Shanmugasundaram、Christy Thoma、Andrew P. Tomaras、Daniel P. Uccello、Alfin Vaz、Donn G. Wishka

  DOI：10.1021/jm2014875

  日期：2012.2.23

  The synthesis and biological activity of a new series of LpxC inhibitors represented by pyridone methylsulfone hydroxamate 2a is presented. Members of this series have improved solubility and free fraction when compared to compounds in the previously described biphenyl methylsulfone hydroxamate series, and they maintain superior Gram-negative antibacterial activity to comparator agents.